Conolidine’s analgesic consequences stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors within the central anxious procedure, conolidine modulates alternate molecular targets. A Science Advancements review found that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availab... https://ernieg148clr1.livebloggs.com/profile